Kelonia Therapeutics develops genetic medicines for a variety of diseases. They are developing a unique gene delivery approach that uses lentiviral vector-like particles to deliver genetic cargo to any desired target tissue. Their iGPS™ technology uses an engineered lentiviral vector particle with a targeting molecule that defines the iGPS particle’s specificity and an optimized fusogen that enables efficient delivery of therapeutic transgenes. Kelonia's initial focus is on developing therapies for solid tumors and hematologic cancers. Their goal is to bring genetic medicines to every patient in need. 

<p>Kelonia Therapeutics develops genetic medicines for a variety of diseases. They are developing a unique gene delivery approach that uses lentiviral vector-like particles to deliver genetic cargo to any desired target tissue. Their iGPS™ technology uses an engineered lentiviral vector particle with a targeting molecule that defines the iGPS particle’s specificity and an optimized fusogen that enables efficient delivery of therapeutic transgenes. Kelonia&#39;s initial focus is on developing therapies for solid tumors and hematologic cancers. Their goal is to bring genetic medicines to every patient in need. </p>


Kelonia Therapeutics

Associate Scientist II, Analytical Development

Scientist II/Sr. Scientist, In Vivo Pharmacology

Join Our Talent Network – Future Roles at Kelonia

This #holiday season, we’re honored to partner with Letters Against Isolation to spread joy to seniors who may be feeling lonely. Senior loneliness is a significant issue, impacting not only mental health but physical health as well. With many seniors living in assisted living facilities and care homes, this initiative offers a simple yet powerful way to make a difference. 
 
Our team came together to write heartfelt, handwritten letters filled with messages of love, hope and holiday cheer. #GiveBack  

#CARTcell therapies genetically engineer a patient's own #Tcells to recognize specific antigens present on #cancer cells. Learn more about our unique approach to developing #invivo CAR-T therapies that would eliminate complex and costly manufacturing processes and make CAR-T more accessible to a broader population of patients: https://lnkd.in/gYv4s83T.    

This International Day of Women and Girls in Science, we unite in calling for women’s full and equal access to and participation in science and celebrate those who are leading action around the world. We are proud of the women that contribute to scientific innovation and the girls aspiring to make a difference. A few of our team members, Yao Wei, MD, Charlotte Adams, and Minja Velimirovic Simon, PhD, share their inspiration for working in #STEM:  
 
#February11 #WomenInScience  

 Astellas Inks Potential $800M Deal with Kelonia for In Vivo Gene Delivery Tech 

 Adeno-Associated Virus Gene Therapy Market Size ... 

In vivo #CARTcell therapies represent the next frontier in genetic medicine - improving upon the speed, safety, cost and accessibility of ex vivo therapies. Our CEO, Kevin Friedman, recently sat down with pharmaphorum's Jonah Comstock to discuss our work and what's next for the growing #invivo CAR-T field: https://lnkd.in/eACKYWxn.

 Recombinant retroviruses, compositions, and methods of use 

Kelonia Therapeutics to Participate in Upcoming Scientific Conferences - Business Wire

Kelonia Therapeutics Appoints Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to Board of Directors

We’re still buzzing from an unforgettable day at TD Garden with Special Olympics Massachusetts! It was an honor to take to the Boston Celtics home court alongside our partner athletes as one of the top fundraising teams for Bio-Ball, uniting for a cause that embodies #inclusion and #teamwork. Huge thanks to the organizers and athletes who made this event so special! 

Our Process Development team is growing! We are excited to add a skilled Downstream PD Senior Scientist to our team who will play a pivotal role in viral vector purification strategies. Apply today if this sounds like the right fit for you: https://lnkd.in/eAX27FGX. #TeamKelonia #Hiring #BiotechJobs

Kelonia Therapeutics to Present Preclinical Data Highlighting Therapeutic Potential of in vivo CAR-T Cell Therapy in Multiple Myeloma - Business Wire

In honor of #MultipleMyelomaAwarenessMonth we raise awareness for the nearly 35,000 people in the U.S. diagnosed each year and to recognize the resilience of those living with this challenging disease. 
 
At Kelonia, we are committed to advancing innovative CAR-T therapies that have the potential to transform treatment options for multiple myeloma and bring new hope to patients. As we continue our work, we stand alongside the Multiple Myeloma community, driving progress toward better outcomes. 
 
Join us in spreading awareness this month and beyond. Learn more: https://keloniatx.com/  
 
#MultipleMyelomaAwareness #CancerResearch  

We're on the ground at BIO 2025 this week! Check out the panel discussion that our CEO, Kevin Friedman, will be participating on tomorrow to learn more about the recent advancements of in vivo #CARtherapies and their potential to transform patient outcomes within oncology and beyond. 
 
Additional details: https://lnkd.in/evbDNRkg  
 
#BIO2025 #celltherapy #genetherapy

 Astellas pledges $800m to Kelonia CAR-T alliance in cancer 

CAR T without the toxicity: Kelonia gets $50M for a new take on cell therapy - MedCity News

Kelonia Therapeutics to Present iGPS® Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting - Business Wire

Astellas Inks Potential $800M Deal with Kelonia for In Vivo Gene Delivery Tech - BioSpace

Astellas’ Xyphos teams with Kelonia on cancer drugs in $800M deal - BioWorld Online

#ICYMI: Our CEO, Kevin Friedman, was recently featured in an article by pharmaphorum exploring the groundbreaking potential of #invivo cell therapies to ease the treatment burden and expand the accessibility of #geneticmedicines. Learn more about the growing field and read the full article here: https://lnkd.in/eACKYWxn.  


            Kelonia Therapeutics 
      

Astellas and Kelonia Partner for $800M In Vivo CAR T Cell Therapies

 Kelonia Therapeutics to Present iGPS® Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting 

 Kelonia Therapeutics to Participate in Upcoming Scientific Conferences 


                            Kelonia Therapeutics to Present iGPS® Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting                        

BioCentury’s 2022 class of emerging companies

Kelonia Therapeutics Announces Upcoming Oral Presentation of Preclinical Data with First Details of iGPS™ Technology at ASGCT Annual Meeting

As #NationalCancerResearchMonth wraps up, we are recognizing the decades of research that has helped advance innovative therapies for patients, including #geneticmedicines and #celltherapy.  
 
A special thank you to the incredible team at Kelonia who have dedicated their time, talent, and passion to advancing cancer research and support our mission to make genetic medicines accessible to every patient in need, when and where they need them. 

Our CEO, Kevin Friedman, will be joining the National Cancer Institute (NCI) Virtual Workshop, “In Vivo Engineering of Immune Cells (IVEIC) for Cancer Immunotherapy,” to discuss the exciting potential of #invivo #CARTcell therapies and our iGPS technology. 

Register and tune in next week: https://lnkd.in/eEHJ2R-F

Learn More

Astellas’ Xyphos, Kelonia ink $800m cancer-focused partnership - BioProcess International

After our move to our new office earlier this year, we were eager to kick off our first holiday season in Dorchester by partnering with a local organization to give back to those in need within our new neighborhood. Thanks to our team and their generous donations, we were able to partner with Pilgrim Congregational Church’s Food Bank to donate Thanksgiving Dinner Baskets to 10 local families and an additional $1400 in grocery store gift cards to support other families in need.  
 
We’re grateful to be part of such a vibrant neighborhood, and look forward to continuing to make a positive impact in the future! #TeamKelonia

 Astellas pursues ‘convertible’ in vivo CAR-T cell therapies with Kelonia Therapeutics 

 Kelonia Therapeutics Raises $50M in Series A Financing 

This week, we will be presenting at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting. Russell McConnell, Director, Discovery Research, will discuss preclinical data that supports the promise of our iGPS gene delivery system to efficiently engineer B cells directly inside the body and treat congenital and infectious diseases. 
 
To learn more, visit: https://lnkd.in/ggYCxkuM 
#ASGCT2025

Kelonia Therapeutics Presents Research Highlighting Potential of iGPS® in vivo Gene Therapy to Bring Safe, Effective CAR T Therapies to Common Medical Practice for  Treatment of All Multiple Myeloma Patients

Xyphos Biosciences & Kelonia Partner to Develop Novel Immuno-Oncology Therapeutics - Contract Pharma

Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics - PR Newswire

Astellas pursues ‘convertible’ in vivo CAR-T cell therapies with Kelonia Therapeutics

We aim to develop transformative #GeneticMedicines leveraging our next-generation gene delivery system to develop a safer, more effective, and more accessible treatment option for patients with #cancer, without the need for chemotherapy. Learn how our revolutionary iGPS® technology can make #CARTcell therapies available to patients when and where they need them: https://lnkd.in/gYv4s83T   

Astellas-owned Xyphos offers more than $800M for Kelonia's in vivo delivery know-how - Fierce Biotech

Xyphos, Kelonia partner for immuno-oncology drug development - Pharmaceutical Technology

 Lymphocyte targeted lentiviral vectors 

Members of our team had a great time at the BostInno Fire Awards Reception last night! We were honored to be recognized as a top #biotech startup alongside other outstanding companies igniting innovation in our community. 
 
Thank you, BostInno, for celebrating our efforts; we are proud to have our roots in #Boston!  
 
#InnoFire


                            Kelonia Therapeutics to Participate in Upcoming Scientific Conferences                        

We are thrilled to spotlight several members of our incredible team for their recent promotions. These well-earned promotions are a testament to the drive, talent, and commitment each of these individuals brings to our mission every day. 
 
Congratulations to Alex Najibi, Josue Figueroa, Joshua Daniel, Kelly Nichols, Anna Piela, and Jeff Wood on your new roles!
 
 #TeamKelonia

Astellas-owned Xyphos offers more than $800M for Kelonia’s in vivo delivery know-how

To put it plainly, our goal at Kelonia is to change what’s possible for genetic medicines. We are building a people-first company with the capability, experience and commitment to bring transformative medicines to every patient in need.  
  
We are grateful for our extraordinary team – one that values both skill and care. Learn more about us: https://keloniatx.com/   

 In vivo daric 

 Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology ... 

 Astellas's CAR Tech Deals Speed Up Its Pursuit of In Vivo Cancer Cell Therapies 

Astellas teams up with startup Kelonia to make ‘in vivo’ cell therapies - BioPharma Dive

 Kelonia Therapeutics on LinkedIn: #invivo #cart #multiplemyeloma #geneticmedicines #aacr24 

Our Focus

Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics

There have been significant advancements in oncology care and treatment, however cancers like #multiplemyeloma remain incurable, and too many patients still face limited options as their disease progresses. The need for more accessible, durable, and transformative treatments has never been greater.  
 
As #MultipleMyelomaAwarenessMonth comes to an end, hear from our CEO & Founder, Kevin Friedman, PhD, discuss the breakthroughs in genetic medicines that have the potential to transform care for all.  

 Astellas' Xyphos teams with Kelonia on cancer drugs in $800M deal 

Astellas’s CAR Tech Deals Speed Up Its Pursuit of In Vivo Cancer Cell Therapies - MedCity News

Kelonia Therapeutics Launches with $50 Million Series A Financing to Pioneer  Precision Targeted Genetic Medicines

Astellas and Kelonia collaborate on in vivo CAR T-cell therapies - BioWorld Online

Gene therapy targeting T-cells shows promise in myeloma animal models - Myeloma Research News

As Cell Therapy Gains Ground, Efforts Emerge to Improve CAR T-Manufacturing

Astellas and Kelonia enter CAR-T cell therapy collaboration worth over $800m - PMLiVE

Astellas teams up with startup Kelonia to make ‘in vivo’ cell therapies

Every experience with cancer is unique and it will take all of us to create a world where we look beyond the disease and see the person before the patient. This is what drives our people-first mission at Kelonia Therapeutics to deliver on the promise of targeted #genetherapy for every person in need. 

On #WorldCancerDay, we join the global community to raise awareness, inspire action, and honor the strength of patients, survivors, and their families. 

Join us in spreading awareness and learn more here: https://lnkd.in/gAJXpEer #UnitedByUnique 

https://www.keloniatx.com/

Kelonia Therapeutics to Present Preclinical Data Highlighting Therapeutic Potential of in vivo CAR-T Cell Therapy in Multiple Myeloma

Kelonia presents ‘compelling evidence’ for transformative multiple myeloma treatment - Labiotech.eu

Kelonia Therapeutics Launches with $50 Million Series A Financing to Pioneer Precision Targeted Genetic Medicines - Business Wire

Gene therapy targeting T-cells shows promise in myeloma animal models

Astellas and Kelonia Partner for $800M In Vivo CAR T Cell Therapies - Genetic Engineering & Biotechnology News

Kelonia Therapeutics Emerges with $50M to Deliver Precision Targeted Genetic Medicines - HIT Consultant

Kelonia Scores $50M to Propel In Vivo Gene Delivery Platform - BioSpace

 Engineered recombinant retroviruses 

 Kelonia Therapeutics on LinkedIn: Last month, we had the privilege of hosting Dr. Kristen… 

 Dual targeted gene therapy 

 Compositions for modifying cells 

A big thank you to our board member, Kristen Hege, for hosting a networking breakfast this morning with some of our talented female scientists and engineers. 
 
The morning was full of meaningful conversations, advice, and mentorship. We’re so grateful for Kristen’s commitment to supporting and mentoring the next generation of women in biotech.
 
At Kelonia, we’re energized by the incredible talent on our team and remain committed to fostering a culture of collaboration and innovation. We’re excited to see where these connections lead and the amazing impact they’ll have along the way!

#TeamKelonia had an incredible time last week at this year's Bio-Ball tournament, and was so excited to be competing, for the second year in a row, alongside the incredibly talented Special Olympics Massachusetts athletes from Lynn! 

This event is always an inspiring reminder of why #inclusion matters. We are proud to have surpassed our fundraising goal by raising $22,685 to support the amazing mission of #SpecialOlympicsMA! Thank you to all those who showed their support, cheered us on, and laced up their shoes to play. 

#BioBall2025 

At Kelonia Therapeutics, our people are the heart of everything we do. Each breakthrough, each milestone, and each step forward is made possible by the dedication, talent, and passion of our team. 
 
This #EmployeeAppreciationDay, we celebrate and thank every member of Team Kelonia for their hard work, innovation, and commitment to transforming the future of #GeneticMedicines. Your contributions make a real impact, and we’re grateful to be on this journey together! 

Rectify Pharmaceuticals Appoints Bharat Reddy as Chief Business Officer - GlobeNewswire

Last week at #BIO2025, our CEO, Kevin Friedman, joined other #invivo #CellTherapy experts to discuss the future of immunotherapy and explore how in vivo CAR therapies have the potential to revolutionize how we treat diseases by programming immune cells directly inside the body.
 
Learn more about Kelonia’s unique in vivo CAR T cell approach and iGPS platform: https://lnkd.in/g8kWVyMV  

 Kelonia Therapeutics to Present Preclinical Data Highlighting Therapeutic Potential of in vivo CAR-T Cell Therapy in ... 

 Kelonia Therapeutics Appoints Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to Board of Directors 

Kelonia Therapeutics to Present iGPS® Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting - Yahoo Finance

Kelonia Therapeutics

Drug notes:

About: